Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan

被引:0
|
作者
Shigeru Honda
Yasuo Yanagi
Hideki Koizumi
Yirong Chen
Satoru Tanaka
Manami Arimoto
Kota Imai
机构
[1] Osaka City University Graduate School of Medicine,Department of Ophthalmology and Visual Sciences
[2] Asahikawa Medical University,Department of Ophthalmology
[3] University of the Ryukyus,Department of Ophthalmology, Graduate School of Medicine
[4] Kantar Health,undefined
[5] Novartis Pharma K.K.,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The chronic eye disorder, neovascular age-related macular degeneration (nAMD), is a common cause of permanent vision impairment and blindness among the elderly in developed countries, including Japan. This study aimed to investigate the disease burden of nAMD patients under treatment, using data from the Japan National Health and Wellness surveys 2009–2014. Out of 147,272 respondents, 100 nAMD patients reported currently receiving treatment. Controls without nAMD were selected by 1:4 propensity score matching. Healthcare Resource Utilisation (HRU), Health-Related Quality of Life (HRQoL), and work productivity loss were compared between the groups. Regarding HRU, nAMD patients had significantly increased number of visits to any healthcare provider (HCP) (13.8 vs. 8.2), ophthalmologist (5.6 vs. 0.8), and other HCP (9.5 vs. 7.1) compared to controls after adjusting for confounding factors. Additionally, nAMD patients had reduced HRQoL and work productivity, i.e., reduced physical component summary (PCS) score (46.3 vs. 47.9), increased absenteeism (18.14% vs. 0.24%), presenteeism (23.89% vs. 12.44%), and total work productivity impairment (33.57% vs. 16.24%). The increased number of ophthalmologist visits were associated with decreased PCS score, increased presenteeism and total work productivity impairment. The current study highlighted substantial burden for nAMD patients, requiring further attention for future healthcare planning and treatment development.
引用
收藏
相关论文
共 50 条
  • [41] Ranibizumab: treatment in patients with neovascular age-related macular degeneration
    Pieramici, Dante J.
    Avery, Robert L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (11) : 1237 - 1245
  • [42] Treatment of neovascular age-related macular degeneration in patients with diabetes
    Cummings, Michael
    Cunha-Vaz, Jose
    CLINICAL OPHTHALMOLOGY, 2008, 2 (02): : 369 - 375
  • [43] Ranibizumab for neovascular age-related macular degeneration
    Gillies, Mark C.
    Wong, Tien Y.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07): : 748 - 749
  • [44] β-blockers and Neovascular Age-related Macular Degeneration
    Yeung, Ling
    Huang, Ting-Shuo
    Lin, Yun-Hsuan
    Hsu, Kuang-Hung
    Huang, Jerry Chien-Chieh
    Sun, Chi-Chin
    OPHTHALMOLOGY, 2017, 124 (03) : 409 - 411
  • [45] Visual outcomes in patients with neovascular age-related macular degeneration
    Tan, Colin S.
    Ngo, Wei Kiong
    Lim, Louis W.
    ACTA OPHTHALMOLOGICA, 2018, 96 (02) : e254 - e254
  • [46] Ranibizumab in neovascular age-related macular degeneration
    Eng, Kenneth T.
    Kertes, Peter J.
    CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) : 451 - 466
  • [47] Radiotherapy for neovascular age-related macular degeneration
    Evans, Jennifer R.
    Igwe, Chinedu
    Jackson, Timothy L.
    Chong, Victor
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (08):
  • [48] Ranibizumab for neovascular age-related macular degeneration
    Hernandez-Pastor, Luis Javier
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (19) : 1805 - 1814
  • [49] Long-acting delivery and therapies for neovascular age-related macular degeneration
    Rowe, Lucas W.
    Ciulla, Thomas A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (08) : 799 - 814
  • [50] Neovascular Age-Related Macular DegenerationPotential Therapies
    Aimee V. Chappelow
    Peter K. Kaiser
    Drugs, 2008, 68 : 1029 - 1036